<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04069013</url>
  </required_header>
  <id_info>
    <org_study_id>19-589</org_study_id>
    <nct_id>NCT04069013</nct_id>
  </id_info>
  <brief_title>Standard vs Mini-PCNL for the Treatment of Stone Disease</brief_title>
  <official_title>Randomized Controlled Trial Comparing Surgical Outcomes Following PCNL and Mini PCNL in the Treatment of Kidney Stones</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized comparison of patient outcomes following standard PCNL versus mini-PCNL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized controlled trial which compares the operative outcomes and
      complications of mini-percutaneous nephrolithotomy (mini-PCNL) versus standard PCNL for renal
      stones. This study will be a multi-institutional, prospective randomized controlled clinical
      trial with patients who have already agreed to undergo PCNL. Patients will be randomized at a
      1:1 ratio to receive either standard PCNL or mini-PCNL, defined as tract sizes of 30 and 16.5
      to 18 French respectively. Patients will be asked to complete pre-operative, and
      post-operative quality of life questionnaires, and to allow collection of one additional vial
      of blood for measurement of factors associated with inflammation. The participating
      institutions are academic medical centers in the United States and Canada that are part of
      the EDGE research consortium.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood loss as estimated by postoperative decreases in hemoglobin Blood loss as estimated by postoperative decreases in hemoglobin Blood Loss</measure>
    <time_frame>Post-operative day 1</time_frame>
    <description>Blood loss as estimated by postoperative decreases in hemoglobin Blood loss as estimated by postoperative decreases in hemoglobin Blood loss as estimated by postoperative decreases in hemoglobin Blood loss as estimated by postoperative decreases in hemoglobin Post-op decreases in hemoglobin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical outcomes</measure>
    <time_frame>30 Days</time_frame>
    <description>Discharge time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication Rates</measure>
    <time_frame>30 Days</time_frame>
    <description>Complication Rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Pelvis Pressures</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Intraoperative renal pelvis pressures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procalcitonin- Inflammatory Markers</measure>
    <time_frame>Post operative day 1</time_frame>
    <description>Procalcitonin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6 Inflammatory Markers</measure>
    <time_frame>Post operative day 1</time_frame>
    <description>IL-6</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Urolithiasis</condition>
  <condition>Kidney Stone</condition>
  <condition>Kidney Calculi</condition>
  <condition>Ureteral Calculi</condition>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Standard PCNL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive a standard PCNL procedure using a 24 fr tract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mini-PCNL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive a mini-PCNL procedure using a 16 fr tract</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PCNL</intervention_name>
    <description>Patients receive standard of care treatment for their urolithiasis using one of two surgical procedures, either standard PCNL or Mini-PCNL</description>
    <arm_group_label>Mini-PCNL</arm_group_label>
    <arm_group_label>Standard PCNL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients planned for PCNL at participating institutions

          -  Age â‰¥ 18 years old

          -  Male and female patients

          -  Patients of all ethnic backgrounds

          -  Stone size 10-20mm

        Patients must be capable of giving informed consent and must be capable and willing to
        enroll and participate fully with the study.

        Exclusion Criteria:

          -  Conversion to open procedure

          -  Multiple access tracts

          -  Anticoagulated or history of coagulopathy

          -  Preoperative ureteral stent or nephrostomy tube placement

          -  Technical problems/impossibility of localizing the stone on the day of intervention

        Patients unable to give informed consent or unwilling to enroll or participate in the study
        will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manoj Monga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manoj Monga, MD</last_name>
    <phone>216-445-8678</phone>
    <email>mongam@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Naveen Kachroo, MD</last_name>
    <phone>216-973-5227</phone>
    <email>kachron@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Manoj Monga, MD</last_name>
      <phone>216-445-8678</phone>
      <email>mongam@ccf.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 15, 2019</study_first_submitted>
  <study_first_submitted_qc>August 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>August 23, 2019</last_update_submitted>
  <last_update_submitted_qc>August 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Percutaneous Nephrolithotomy</keyword>
  <keyword>PCNL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Ureteral Calculi</mesh_term>
    <mesh_term>Ureterolithiasis</mesh_term>
    <mesh_term>Calculi</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

